One of the greatest things about a human life is how you can always make it better in one way or the other. This, in particular, allows us to hit upon some huge milestones, and the same is proven by a well-constructed testimony called technology. The reason why technology enjoys such an esteemed stature among all our achievements, as we know, is predicated upon its uniqueness skill-set. However, it is also, at the same time, inspired by manner in which those skills were executed. Now that you think about it, the latter component was, in fact, what realized a spectrum-wide presence for the creation, including a notable appearance on our healthcare block. Technology’s linkup with healthcare was so perfectly-timed because it came right when the sector was starting to struggle against an obsolete structure. Fortunately, the horizons are going to transform dramatically under the new regime, but even after doing so much on the back of technology’s ingenious ideas, the famous medtech revolution has somehow continued to get bigger to this day. If anything, one recent funding does a lot to reinforce the stated pattern moving forward.
3T Biosciences, a San Francisco-based Stanford University spinout, has successfully raised $40 million in Series A financing. The round, which saw close participation from the likes of Westlake Village BioPartners and Lightspeed Venture Partners, is expected to fund the company’s bid for an improved cancer immunotherapy landscape. Since starting out in 2017, 3T Biosciences has moved steadily towards solving the targeting issues that we usually associate with most existing immunotherapies. You see, while these therapies are designed to address targets on the surface of a tumor cell, they don’t necessarily look into the depths and identify any novel targets to optimize the treatment’s overall effectiveness. On the other hand, 3T biosciences uses an approach where T cells are really at the heart of everything. The company combines these cells’ tendency to alert the immunity system against any foreign elements with a technology that consistently produces new targets for them. By doing so, it allows the creation of many new therapies for treating solid tumors as well as diseases tied to the immune system. Interestingly enough, the stated technology is also well-equipped in regards to screening TCRs and zeroing in on the ones that are most highly selective and can avoid reacting with off-target proteins. This is supposed to pave the way for therapies that are safer, more specific, and open to larger doses.
“On behalf of the entire team at 3T Biosciences, we are thrilled to launch with support from this outstanding syndicate of blue-chip investors. 3T’s best-in-class 3T-TRACE discovery platform has the ability to transform the treatment of cancers and beyond. The combination of the TCR-mimetic discovery platform with the 3T-TRACE platform uniquely positions 3T to rapidly generate therapeutics targeting pHLA targets that are devoid of off-target cross-reactivity targeting.” said Dr. Stefan J. Scherer, president and CEO of 3T Biosciences.
While cancer is really the focus for now, 3T Biosciences’ future plan does include a foray into other therapeutic areas as well.
